Clinical Trial Update: Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms [Phase 1, Phase 2]

View source ↗

Summary

Pacritinib is being studied in Phase 1/2 trials for myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms in adults and participants aged 1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes

Drugs mentioned

• Pacritinib (pacritinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: RECRUITING